Evidence map›Paper›PMID 27746911›Full record

ReviewF1000Research2016

Getting to S: CDK functions and targets on the path to cell-cycle commitment.

Robert P Fisher

Abstract readReview
In one paragraph

Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Frontiers in pharmacology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Robert P FisherDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

Chemical Genetics of Transcriptional Regulation by CDKs in Human CellsR01GM104291 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FISHER, ROBERT P · 2014 to 2017
$1.3M
Chemical Genetic Analysis of the Human Cell CycleR01GM105773 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FISHER, ROBERT P · 2013 to 2016
$1.3M
NIGMS NIH HHS R01 GM104291NIGMS NIH HHS R01 GM105773
6 · The paper itself

Abstract

How and when eukaryotic cells make the irrevocable commitment to divide remain central questions in the cell-cycle field. Parallel studies in yeast and mammalian cells seemed to suggest analogous control mechanisms operating during the G1 phase-at Start or the restriction (R) point, respectively-to integrate nutritional and developmental signals and decide between distinct cell fates: cell-cycle arrest or exit versus irreversible commitment to a round of division. Recent work has revealed molecular mechanisms underlying this decision-making process in both yeast and mammalian cells but also cast doubt on the nature and timing of cell-cycle commitment in multicellular organisms. These studies suggest an expanded temporal window of mitogen sensing under certain growth conditions, illuminate unexpected obstacles and exit ramps on the path to full cell-cycle commitment, and raise new questions regarding the functions of cyclin-dependent kinases (CDKs) that drive G1 progression and S-phase entry.

Indexed as

CDKscell cyclecell cycle checkpointscyclin-dependent kinasesG1 progressionS-phase entry

Identifiers

PMID27746911
PMCPMC5040153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.